ArticleMolecular psychiatry2026
Dynamic single-cell transcriptomic analysis of peripheral blood mononuclear cells identifies novel biomarkers for autoimmune encephalitis.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Autoimmune encephalitis (AE) is a severe neurological disease characterized by diverse clinical symptoms. Current routine imaging and laboratory assessments show low disease specificity, resulting in a high misdiagnosis rate. We dynamically characterized the single-cell transcriptome of peripheral immune cells in the acute phase of AE and six-month sequential treatment. Depletion of natural killer T (NKT) cells, specifically of the NKT-6 subpopulation, was an AE hallmark that effectively differentiated AE patients from healthy controls. Exhausted NKT in AE was independently validated to be disease-specific using an independent clinical cohort of neurological and psychiatric conditions, including neuromyelitis optica spectrum disorder, multiple sclerosis, viral encephalitis, and major depressive disorder. In addition, diminished NKT cells and NKT-6 subpopulation levels gradually reversed with clinical improvement during a 6-month follow-up. Moreover, gene modules derived from NKT cells reflected disease progression. Our findings strongly support the notion that decreased NKT cell and NKT-6 subpopulation levels are potential novel biomarkers for AE diagnosis and disease progression.
Identifiers
42443389What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.